Beneficiaries say Inflation Reduction Act will worsen access, affordability challenges.

When other countries pay less for drugs, they are free-riding on American innovation and our willingness to pay for new treatments. Forcing manufacturers to charge the same price that these other countries do would backfire. Instead, policymakers should use trade negotiations to pressure other wealthy countries to pay their fair share. No Patient Left Behind wrote to the Office of the United States Trade urging an end to unfair trade practices in drug pricing.

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

An independent and autonomous FDA is a key part of ensuring that the biotech innovation ecosystem can continue to thrive. As an agency, it is the gold standard globally for determining risk-reward benefit in therapies for patients, and the world looks to it to lead the way. The people at the FDA are trying hard to make sure that we actually make progress, and their work is a service to the American public.

No Patient Left Behind wrote to the Office of the United States Trade Representative regarding the 2025 Special 301 Review, urging the agency to use its tariff and market access tools to force OECD countries to pay their fair share for medical innovation and end the free-riding of American biomedical innovation.

America is the global leader in biomedical innovation because it has a market that values new medicines. When other countries pay less, they are free-riding on our willingness to pay for new treatments. Forcing drug manufacturers to charge the same price that these other countries mandate would backfire. Instead, policymakers should use trade negotiations to pressure other wealthy countries to pay their fair share.

A new survey demonstrates that a majority of consumers want health plans to lower out-of- pocket costs, but are concerned state government price controls will harm access and not reduce costs

The independence and autonomy of the Food and Drug Administration (FDA) is a key part of ensuring that the biotech innovation ecosystem can continue to thrive. As an agency, it is the gold standard globally for determining risk-reward benefit in therapies for patients, and the world looks to it to lead the way. The people at the FDA facilitate the medical progress we all enjoy, and their work is a service to the American public.

There is an assault on the foundation of U.S. science. Recent actions—including arbitrarily restricting scientists' ability to speak and travel and stalling the dispersal of previously awarded NIH and NSF funds—are more than bureaucratic disruptions. They are an assault on the foundation of biomedical and technological progress.

No Patient Left Behind (NPLB) wrote to the Centers for Medicare and Medicaid services (CMS) urging the agency to allow Medicare to cover anti-obesity medications (AOMs) and to strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.

When assessing the viability of an investment, investors attempt to calculate the business’s or product’s net-present value (NPV). The NPV combines a project’s likelihood of success with an estimate of the money it may make over time to determine its present value to investors. The price-setting provisions of the IRA reduce the NPV of any drug candidate at launch by 40%. If investors aren’t confident they will earn a return on their investment, they won’t invest in new drug candidates, and most ideas will never leave the laboratory.

CBO’s ability to correctly model investor decision-making is vital to our country’s ability to establish policies that achieve lasting biomedical affordability and continued innovation. In support of CBO’s efforts to improve its model, this letter emphasizes a number of economic and financial first principles, notably that investment is incentivized by expected returns based on discounted profits, not revenue, and adjusted for expected dilution from financings.